277 related articles for article (PubMed ID: 31564830)
1. Dexmedetomidine protects H9c2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation-induced intracellular calcium overload and apoptosis through regulating FKBP12.6/RyR2 signaling.
Yuan M; Meng XW; Ma J; Liu H; Song SY; Chen QC; Liu HY; Zhang J; Song N; Ji FH; Peng K
Drug Des Devel Ther; 2019; 13():3137-3149. PubMed ID: 31564830
[TBL] [Abstract][Full Text] [Related]
2. Dexmedetomidine reversed hypoxia/reoxygenation injury-induced oxidative stress and endoplasmic reticulum stress-dependent apoptosis of cardiomyocytes via SIRT1/CHOP signaling pathway.
Zhang Y; Zhao Q; Li X; Ji F
Mol Cell Biochem; 2021 Jul; 476(7):2803-2812. PubMed ID: 33725228
[TBL] [Abstract][Full Text] [Related]
3. HSP70 protects H9C2 cells from hypoxia and reoxygenation injury through STIM1/IP3R.
Liu T; Juan Z; Xia B; Ren G; Xi Z; Hao J; Sun Z
Cell Stress Chaperones; 2022 Sep; 27(5):535-544. PubMed ID: 35841499
[TBL] [Abstract][Full Text] [Related]
4. Dexmedetomidine Attenuates Cellular Injury and Apoptosis in H9c2 Cardiomyocytes by Regulating p-38MAPK and Endoplasmic Reticulum Stress.
Zhu Z; Ling X; Zhou H; Zhang C; Yan W
Drug Des Devel Ther; 2020; 14():4231-4243. PubMed ID: 33116411
[TBL] [Abstract][Full Text] [Related]
5. Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro.
Chang JH; Jin MM; Liu JT
Biomed Pharmacother; 2020 Jul; 127():110188. PubMed ID: 32407987
[TBL] [Abstract][Full Text] [Related]
6. Dexmedetomidine inhibits apoptosis of astrocytes induced by oxygen-glucose deprivation via targeting JAK/STAT3 signal pathway.
Feng P; Zhang A; Su M; Cai H; Wang X; Zhang Y
Brain Res; 2021 Jan; 1750():147141. PubMed ID: 33017590
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of dexmedetomidine on hypoxia/reoxygenation injury in cardiomyocytes by regulating the CHOP signaling pathway.
Shi X; Liu Z; Li J
Mol Med Rep; 2020 Oct; 22(4):3307-3315. PubMed ID: 32945482
[TBL] [Abstract][Full Text] [Related]
8. Matrine alleviates AGEs- induced cardiac dysfunctions by attenuating calcium overload via reducing ryanodine receptor 2 activity.
Wang J; Tang Z; Zhang Y; Qiu C; Zhu L; Zhao N; Liu Z
Eur J Pharmacol; 2019 Jan; 842():118-124. PubMed ID: 30339815
[TBL] [Abstract][Full Text] [Related]
9. Dexmedetomidine protects cardiac microvascular endothelial cells from the damage of ogd/r through regulation of the pparδ-mediated autophagy.
Shao Q; Xia J; Wu P; Ying J
Microcirculation; 2021 May; 28(4):e12675. PubMed ID: 33377581
[TBL] [Abstract][Full Text] [Related]
10. Dexmedetomidine Protects Cardiomyocytes against Hypoxia/Reoxygenation Injury by Suppressing TLR4-MyD88-NF-
Gao JM; Meng XW; Zhang J; Chen WR; Xia F; Peng K; Ji FH
Biomed Res Int; 2017; 2017():1674613. PubMed ID: 29359143
[TBL] [Abstract][Full Text] [Related]
11. Dexmedetomidine alleviates hepatic injury via the inhibition of oxidative stress and activation of the Nrf2/HO-1 signaling pathway.
Zhao Y; Kong GY; Pei WM; Zhou B; Zhang QQ; Pan BB
Eur Cytokine Netw; 2019 Sep; 30(3):88-97. PubMed ID: 31957703
[TBL] [Abstract][Full Text] [Related]
12. Dexmedetomidine at a dose of 1 µM attenuates H9c2 cardiomyocyte injury under 3 h of hypoxia exposure and 3 h of reoxygenation through the inhibition of endoplasmic reticulum stress.
Zhu Z; Ling X; Zhou H; Zhang C
Exp Ther Med; 2021 Feb; 21(2):132. PubMed ID: 33376514
[TBL] [Abstract][Full Text] [Related]
13. Dexmedetomidine post-treatment attenuates cardiac ischaemia/reperfusion injury by inhibiting apoptosis through HIF-1α signalling.
Peng K; Chen WR; Xia F; Liu H; Meng XW; Zhang J; Liu HY; Xia ZY; Ji FH
J Cell Mol Med; 2020 Jan; 24(1):850-861. PubMed ID: 31680420
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Stim1 reduced intracellular calcium concentration and attenuated hypoxia/reoxygenation induced apoptosis in H9C2 cells.
He F; Wu Q; Xu B; Wang X; Wu J; Huang L; Cheng J
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29089467
[TBL] [Abstract][Full Text] [Related]
15. Dexmedetomidine attenuates ischemia and reperfusion-induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53-upregulated modulator of apoptosis (PUMA) signaling signaling.
Yang FY; Zhang L; Zheng Y; Dong H
Bioengineered; 2022 Jan; 13(1):1377-1387. PubMed ID: 34974801
[TBL] [Abstract][Full Text] [Related]
16. Dexmedetomidine protects against oxygen-glucose deprivation/reoxygenation injury-induced apoptosis via the p38 MAPK/ERK signalling pathway.
Wang K; Zhu Y
J Int Med Res; 2018 Feb; 46(2):675-686. PubMed ID: 29210287
[TBL] [Abstract][Full Text] [Related]
17. Dexmedetomidine protects cardiomyocytes against hypoxia/reoxygenation injury via multiple mechanisms.
Cai S; Liu Y; Cheng Y; Yuan J; Fang J
J Clin Lab Anal; 2022 Jul; 36(7):e24119. PubMed ID: 34882841
[TBL] [Abstract][Full Text] [Related]
18. Dexmedetomidine protects hepatic cells against oxygen-glucose deprivation/reperfusion injury via lncRNA CCAT1.
Zhou Z; Chen Q; Wan L; Zheng D; Li Z; Wu Z
Cell Biol Int; 2018 Sep; 42(9):1250-1258. PubMed ID: 29851220
[TBL] [Abstract][Full Text] [Related]
19. Dexmedetomidine protects H9C2 rat cardiomyocytes against hypoxia/reoxygenation injury by regulating the long non-coding RNA colon cancer-associated transcript 1/microRNA-8063/Wnt/β-catenin axis.
Liu C; Xu R
Bioengineered; 2022 May; 13(5):13300-13311. PubMed ID: 35635079
[TBL] [Abstract][Full Text] [Related]
20. Dexmedetomidine protects H9C2 against hypoxia/reoxygenation injury through miR-208b-3p/Med13/Wnt signaling pathway axis.
Wang Z; Yang Y; Xiong W; Zhou R; Song N; Liu L; Qian J
Biomed Pharmacother; 2020 May; 125():110001. PubMed ID: 32070878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
